Cancer treatment and survivorship statistics, 2019

Abstract

effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost two-thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow-up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care.

Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study

“…As of January 1, 2016, there were estimated to be over 15.5 million cancer survivors in the USA [1]. The number of survivors will increase significantly as a result of ageing of the population, increased cancer detection and improved treatments.…”

“…The number of survivors will increase significantly as a result of ageing of the population, increased cancer detection and improved treatments. By January 1, 2026, the number of survivors in the USA is estimated to exceed 20 million [1]. The most prevalent groups are survivors of breast, prostate and colorectal cancer, melanoma and lymphoma [1].…”

“…By January 1, 2026, the number of survivors in the USA is estimated to exceed 20 million [1]. The most prevalent groups are survivors of breast, prostate and colorectal cancer, melanoma and lymphoma [1].…”

“…Survivors may experience a broad range of issues after completing treatments, including physical, emotional, practical and social consequences [1,2]. These may be shortterm or long-lasting.…”

FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma

“…1 Authors contributed equally to this work.2 However, its roles in nasopharyngeal carcinoma (NPC) are poorly understood.Although several studies have shown that FOXC2 promotes the progression of NPC, the underlying molecular mechanism remains largely unknown. Here, we have shown that FOXC2 interacted with YAP and TEAD, and activated YAP signaling.…”